Pertuzumab binds to the extracellular dimerization domain of the HER2 protein, preventing it from pairing with other HER2 receptors. This inhibition blocks the downstream signaling pathways that promote cell growth and survival, thereby inhibiting the proliferation of cancer cells. Additionally, pertuzumab can mediate antibody-dependent cellular cytotoxicity (ADCC), where immune cells are recruited to destroy the cancer cells.
